EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives

Michelle M Dugan iD, Matthew C Perez, Lilit Karapetyan, Jonathan S Zager iD

Cancer Management and Research · 2024-07 · Volume 16 · 933-939

DOI: 10.2147/cmar.s325514 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Management and Research, 2024-07. Verfasst von Michelle M Dugan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BRAF inhibitorBRAF-mutant melanomaMEK inhibitorcombination BRAF therapymetastatic melanomatriple therapy

Autor:innen und Institutionen

  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.

ORCID-Profile: Michelle M Dugan, Jonathan S Zager

Zitieren

APA

Dugan, M. M., Perez, M. C., Karapetyan, L., & Zager, J. S. (2024). Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives. Cancer Management and Research, Volume 16, 933-939. https://doi.org/10.2147/cmar.s325514

Vancouver

Dugan MM, Perez MC, Karapetyan L, Zager JS. Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives. Cancer Management and Research. 2024;Volume 16:933-939. doi:10.2147/cmar.s325514

BibTeX
@article{Dugan2024,
  author = {Dugan, Michelle M and Perez, Matthew C and Karapetyan, Lilit and Zager, Jonathan S},
  title = {Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives},
  journal = {Cancer Management and Research},
  year = {2024},
  volume = {Volume 16},
  pages = {933--939},
  doi = {10.2147/cmar.s325514}
}
Kostenlos starten →